The acquisition culminates a year-long collaborative research agreement between VDDI and ILB that established the proof of principle for the technology for use in human and animal infectious diseases.Evidence from this collaboration demonstrates the potential for this technology to enhance the stability of medical peptides,reduce previously identified side-effect liabilities inherent to other medical peptides,while retaining or enhancing the antimicrobial activity of these compounds.Based upon these results,VDDI is poised to proceed to animal testing of lead compounds generated during the VDDI/ILB collaboration.
展开▼
